 A panel of the FDAs outside experts voted 9-3 that Acadia Pharmaceuticals Incs NASDAQ: ACAD pimavanserin doesnt appear to be effective at treating patients with Alzheimers-related psychosis. The drug, Nuplazid, is already indicated for Parkinsons-. 